{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:31:42Z","timestamp":1790767902970,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["yyqdkt2019-19"],"award-info":[{"award-number":["yyqdkt2019-19"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejphar.2020.173562","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T11:18:57Z","timestamp":1600255137000},"page":"173562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome)"],"prefix":"10.1016","volume":"888","author":[{"given":"Weijing","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/ped.12636","article-title":"Sanfilippo syndrome: overall review","volume":"57","author":"Andrade","year":"2015","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.ejphar.2020.173562_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omtm.2017.05.009","article-title":"Clearance of heparan sulfate and attenuation of CNS pathology by intracerebroventricular BMN 250 in Sanfilippo type B mice","volume":"6","author":"Aoyagi-Scharber","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2011.01.015","article-title":"Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment","volume":"103","author":"Arfi","year":"2011","journal-title":"Mol. Genet. Metabol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10545-009-9029-2","article-title":"Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones","volume":"33","author":"Arfi","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173562_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002296","article-title":"Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice","volume":"3","author":"Ausseil","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2020.173562_bib6","first-page":"100604","article-title":"Intravenous delivery for treatment of mucopolysaccharidosis type I: a comparison of AAV serotypes 9 and rh10","volume":"24","author":"Belur","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/jcm9030644","article-title":"Neuronal and astrocytic differentiation from Sanfilippo C syndrome iPSCs for disease modeling and drug development","volume":"9","author":"Beneto","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2020.173562_bib8","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.scr.2019.101616","article-title":"Generation of two compound heterozygous HGSNAT-mutated lines from healthy induced pluripotent stem cells using CRISPR\/Cas9 to model Sanfilippo C syndrome","volume":"41","author":"Beneto","year":"2019","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.ejphar.2020.173562_bib9","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.scr.2019.101668","article-title":"Generation of two NAGLU-mutated homozygous cell lines from healthy induced pluripotent stem cells using CRISPR\/Cas9 to model Sanfilippo B syndrome","volume":"42","author":"Beneto","year":"2020","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.ejphar.2020.173562_bib10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 administration in nonhuman primates: promising routes and vectors for which neurological diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib11","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.ymgme.2017.12.038","article-title":"Interleukin-1 plays a central role in behaviour abnormalities in mucopolysaccharidosis type III (MPS III)","volume":"123","author":"Bigger","year":"2018","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejphar.2020.173562_bib12","doi-asserted-by":"crossref","first-page":"13654","DOI":"10.1038\/srep13654","article-title":"EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome","volume":"5","author":"Canals","year":"2015","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173562_bib13","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.22643","article-title":"Genistein in Sanfilippo disease: a randomized controlled crossover trial","volume":"71","author":"de Ruijter","year":"2012","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173562_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10545-011-9342-4","article-title":"Genistein supplementation in patients affected by Sanfilippo disease","volume":"34","author":"Delgadillo","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ejhg.2009.144","article-title":"Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease","volume":"18","author":"Dziedzic","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2020.173562_bib17","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.ymgme.2016.11.089","article-title":"Preliminary findings of a twenty-six week or longer intracerebroventricular infusion study of BMN 250 administered once every 2 weeks in a canine model of mucopolysaccharidosis type IIIB","volume":"120","author":"Ellinwood","year":"2017","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejphar.2020.173562_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omtm.2019.04.001","article-title":"Pre-clinical safety and efficacy of lentiviral vector-mediated ex vivo stem cell gene therapy for the treatment of mucopolysaccharidosis IIIA","volume":"13","author":"Ellison","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ejphar.2020.173562_bib19","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/TACG.S57672","article-title":"Sanfilippo syndrome: causes, consequences, and treatments","volume":"8","author":"Fedele","year":"2015","journal-title":"Appl. Clin. Genet."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib20","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.ymgme.2019.11.129","article-title":"Interim results of Transpher A, a multicenter, single-dose, phase 1\/2 clinical trial of ABO-102 gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA)","volume":"129","author":"Flanigan","year":"2020","journal-title":"Mol. Genet. Metabol."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11011-017-0111-4","article-title":"How close are we to therapies for Sanfilippo disease?","volume":"33","author":"Gaffke","year":"2018","journal-title":"Metab. Brain Dis."},{"issue":"10","key":"10.1016\/j.ejphar.2020.173562_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109596","article-title":"Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4","volume":"9","author":"Goodall","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ejphar.2020.173562_bib23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1089\/hum.2018.189","article-title":"An improved adeno-associated virus vector for neurological correction of the mouse model of mucopolysaccharidosis IIIA","volume":"30","author":"Gray","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13346-019-00683-6","article-title":"Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B","volume":"10","author":"Grover","year":"2020","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"10.1016\/j.ejphar.2020.173562_bib25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jpeds.2011.04.040","article-title":"Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study","volume":"159","author":"Guffon","year":"2011","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejphar.2020.173562_bib26","first-page":"37","article-title":"Pentosan polysulfate treatment of mucopolysaccharidosis type IIIA mice","volume":"43","author":"Guo","year":"2019","journal-title":"JIMD Rep"},{"key":"10.1016\/j.ejphar.2020.173562_bib27","first-page":"100510","article-title":"Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice","volume":"21","author":"Gustavsson","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/jcm9020344","article-title":"Molecular bases of neurodegeneration and cognitive decline, the major burden of Sanfilippo disease","volume":"9","author":"Heon-Roberts","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/brain\/awx311","article-title":"Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy","volume":"141","author":"Holley","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2020.173562_bib30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2741\/4463","article-title":"Glycosaminoglycans and mucopolysaccharidosis type III","volume":"21","author":"Jakobkiewicz-Banecka","year":"2016","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejphar.2020.173562_bib31","first-page":"100554","article-title":"Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats","volume":"22","author":"Janson","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","article-title":"A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA","volume":"118","author":"Jones","year":"2016","journal-title":"Mol. Genet. Metabol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173562_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2020.06.004","article-title":"Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses","volume":"130","author":"Jones","year":"2020","journal-title":"Mol. Genet. Metabol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2016.04.002","article-title":"N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice","volume":"118","author":"Kaidonis","year":"2016","journal-title":"Mol. Genet. Metabol."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metabol."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173562_bib36","doi-asserted-by":"crossref","first-page":"770","DOI":"10.4014\/jmb.1911.11009","article-title":"Biological synthesis of genistein in Escherichia coli","volume":"30","author":"Kim","year":"2019","journal-title":"J. Microbiol. Biotechnol."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173562_bib37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2013.06.012","article-title":"High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system","volume":"109","author":"Kim","year":"2013","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejphar.2020.173562_bib38","series-title":"Bone Marrow Transpl","article-title":"Poor cognitive outcome of eleven children with Sanfilippo syndrome after bone marrow transplantation and successful engraftment","author":"Klein","year":"1995"},{"key":"10.1016\/j.ejphar.2020.173562_bib39","first-page":"100578","article-title":"Hematopoietic stem cell transplantation in mucopolysaccharidosis type IIIA: a case description and comparison with a genotype-matched control group","volume":"23","author":"Kohn","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173562_bib40","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1515\/jpem-2019-0505","article-title":"Mucopolysaccharidosis III in Mainland China: natural history, clinical and molecular characteristics of 34 patients","volume":"33","author":"Kong","year":"2020","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2020.173562_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbmt.2004.12.246","article-title":"Treatment of pediatric patients with Sanfilippo syndrome (MPS IIIA and IIIB) with unrelated umbilical cord blood transplantation","volume":"11","author":"Kurtzberg","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173562_bib42","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/mt.2012.82","article-title":"Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice","volume":"20","author":"Langford-Smith","year":"2012","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173562_bib43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00109-020-01935-6","article-title":"Lysosomal storage diseases: current therapies and future alternatives","volume":"98","author":"Leal","year":"2020","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ejphar.2020.173562_bib44","doi-asserted-by":"crossref","DOI":"10.1089\/cmb.2019.0443","article-title":"Drug-target interaction network analysis of gene-phenotype connectivity maintained by genistein","author":"Li","year":"2020","journal-title":"J. Comput. Biol."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173562_bib45","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/15548627.2018.1474313","article-title":"Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency","volume":"14","author":"Lotfi","year":"2018","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/diseases7020037","article-title":"Gene therapy today and tomorrow","volume":"7","author":"Lundstrom","year":"2019","journal-title":"Diseases"},{"issue":"15","key":"10.1016\/j.ejphar.2020.173562_bib47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.4155\/bio-2019-0095","article-title":"Robust LC-MS\/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA","volume":"11","author":"Makower","year":"2019","journal-title":"Bioanalysis"},{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2009.06.013","article-title":"Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice","volume":"98","author":"Malinowska","year":"2009","journal-title":"Mol. Genet. Metabol."},{"issue":"12","key":"10.1016\/j.ejphar.2020.173562_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014192","article-title":"Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease","volume":"5","author":"Malinowska","year":"2010","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ejphar.2020.173562_bib50","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/hum.2019.217","article-title":"In vivo gene therapy for mucopolysaccharidosis type III (Sanfilippo syndrome): a new treatment horizon","volume":"30","author":"Marco","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"9","key":"10.1016\/j.ejphar.2020.173562_bib51","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/ajmg.a.34146","article-title":"Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT)","volume":"155A","author":"Marucha","year":"2011","journal-title":"Am. J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10545-013-9668-1","article-title":"Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease","volume":"37","author":"Matalonga","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib53","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.ymgme.2017.12.091","article-title":"Pharmacology of BMN 250 administered via intracerebroventricular infusion once every 2 weeks for twenty-six weeks or longer in a canine model of mucopolysaccharidosis type IIIB","volume":"123","author":"Matthew","year":"2018","journal-title":"Mol. Genet. Metabol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib54","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3390\/ijms20020304","article-title":"The role of dimethyl sulfoxide (DMSO) in gene expression modulation and glycosaminoglycan metabolism in lysosomal storage disorders on an example of mucopolysaccharidosis","volume":"20","author":"Moskot","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib55","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.ymgme.2017.12.270","article-title":"ICV-administered BMN 250 (NAGLU-IGF2) is well tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB)","volume":"123","author":"Muschol","year":"2018","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejphar.2020.173562_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.parkreldis.2019.12.007","article-title":"Oral trehalose maybe helpful for patients with spinocerebellar ataxia 3 and should be better evaluated","volume":"70","author":"Noorasyikin","year":"2020","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.ejphar.2020.173562_bib57","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jnc.14632","article-title":"The role of innate immunity in mucopolysaccharide diseases","volume":"148","author":"Parker","year":"2019","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib58","doi-asserted-by":"crossref","first-page":"e11185","DOI":"10.15252\/emmm.201911185","article-title":"Haematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIA","volume":"12","author":"Parker","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13023-020-01363-2","article-title":"Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry","volume":"15","author":"Patterson","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ejphar.2020.173562_bib60","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0883073809344222","article-title":"Long-term miglustat therapy in children with Niemann-Pick disease type C","volume":"25","author":"Patterson","year":"2010","journal-title":"J. Child Neurol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib61","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v8i2.2045","article-title":"A cure for Sanfilippo syndrome? A summary of current therapeutic approaches and their promise","volume":"8","author":"Pearse","year":"2020","journal-title":"Med Res Arch"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12017-018-8482-1","article-title":"Correction of huntington's disease phenotype by genistein-induced autophagy in the cellular model","volume":"20","author":"Pierzynowska","year":"2018","journal-title":"NeuroMolecular Med."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173562_bib63","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.ejhg.5201623","article-title":"Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses","volume":"14","author":"Piotrowska","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib64","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.curtheres.2008.04.002","article-title":"Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients","volume":"69","author":"Piotrowska","year":"2008","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173562_bib65","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1182\/blood-2008-03-140830","article-title":"Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes","volume":"112","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2020.173562_bib66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omtm.2019.05.008","article-title":"Differential uptake of NAGLU-IGF2 and unmodified NAGLU in cellular models of Sanfilippo syndrome type B","volume":"14","author":"Prill","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2020.173562_bib67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2007.06.016","article-title":"Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA","volume":"92","author":"Roberts","year":"2007","journal-title":"Mol. Genet. Metabol."},{"issue":"8","key":"10.1016\/j.ejphar.2020.173562_bib68","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/hmg\/ddx058","article-title":"Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID","volume":"26","author":"Roca","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib69","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2020.173562_bib70","doi-asserted-by":"crossref","first-page":"g3434","DOI":"10.1136\/bmj.g3434","article-title":"What is an open label trial?","volume":"348","author":"Sedgwick","year":"2014","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ejphar.2020.173562_bib71","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/mt.2013.141","article-title":"Myeloid\/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease","volume":"21","author":"Sergijenko","year":"2013","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173562_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00710053","article-title":"Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation","volume":"18","author":"Shapiro","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173562_bib73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40266-020-00769-8","article-title":"Bimatoprost implant: first approval","volume":"37","author":"Shirley","year":"2020","journal-title":"Drugs Aging"},{"issue":"7","key":"10.1016\/j.ejphar.2020.173562_bib74","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1005526628598","article-title":"Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling","volume":"22","author":"Sivakumur","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejphar.2020.173562_bib75","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.omtm.2020.04.023","article-title":"Lentiviral hematopoietic stem cell gene therapy corrects murine pompe disease","volume":"17","author":"Stok","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejphar.2020.173562_bib77","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2020.173562_bib78","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/brain\/awy126","article-title":"A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency","volume":"141","author":"Tordo","year":"2018","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib79","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10545-008-0838-5","article-title":"Sanfilippo syndrome: a mini-review","volume":"31","author":"Valstar","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ejphar.2020.173562_bib80","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1021\/acsnano.0c00666","article-title":"Cationic amphiphilic drugs boost the lysosomal escape of small nucleic acid therapeutics in a nanocarrier-dependent manner","volume":"14","author":"Van de Vyver","year":"2020","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.ejphar.2020.173562_bib81","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/BF01800232","article-title":"Bone marrow transplantation for Sanfilippo disease type B","volume":"15","author":"Vellodi","year":"1992","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6648","key":"10.1016\/j.ejphar.2020.173562_bib82","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/38410","article-title":"Gene therapy -- promises, problems and prospects","volume":"389","author":"Verma","year":"1997","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib83","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/prep.2000.1361","article-title":"Expression and characterization of human recombinant and alpha-N-acetylglucosaminidase","volume":"21","author":"Weber","year":"2001","journal-title":"Protein Expr. Purif."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib84","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2018.12.003","article-title":"Final results of the phase 1\/2, open-label clinical study of intravenous recombinant human N-acetyl-alpha-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB","volume":"126","author":"Whitley","year":"2019","journal-title":"Mol. Genet. Metabol."},{"issue":"2","key":"10.1016\/j.ejphar.2020.173562_bib85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","article-title":"Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: a phase IIb randomized trial","volume":"126","author":"Wijburg","year":"2019","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.ejphar.2020.173562_bib86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nbd.2014.03.001","article-title":"Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice","volume":"67","author":"Williams","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207836","article-title":"BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis","volume":"14","author":"Yogalingam","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2020.173562_bib88","doi-asserted-by":"crossref","DOI":"10.1007\/s12311-020-01150-6","article-title":"Trehalose in machado-joseph disease: safety, tolerability, and efficacy","author":"Zaltzman","year":"2020","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib89","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13023-018-0796-4","article-title":"Epidemiology of Sanfilippo syndrome: results of a systematic literature review","volume":"13","author":"Zelei","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2020.173562_bib90","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/prep.2000.1230","article-title":"Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells","volume":"19","author":"Zhao","year":"2000","journal-title":"Protein Expr. Purif."},{"issue":"24","key":"10.1016\/j.ejphar.2020.173562_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202000416","article-title":"Single siRNA nanocapsules for effective siRNA brain delivery and glioblastoma treatment","volume":"32","author":"Zou","year":"2020","journal-title":"Adv. Mater."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920306543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:18:31Z","timestamp":1778653111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920306543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":91,"alternative-id":["S0014299920306543"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173562","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173562"}}